Publications by authors named "William Lennox"

Claim this Profile
C
Comparison of pharmaceutical properties and biological activities of prednisolone, deflazacort, and vamorolone in DMD disease models.
Grace Liu, Philip Lipari, Anna Mollin, Stephen Jung, Irina Teplova, William Lennox

Hum Mol Genet· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SAR studies toward discovery of emvododstat (PTC299), a potent dihydroorotate dehydrogenase (DHODH) inhibitor.
Ramil Y Baiazitov, Hongyan Qi, Tamil Arasu, William Lennox, Liangxian Cao

Eur J Med Chem· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The combination of the tubulin binding small molecule PTC596 and proteasome inhibitors suppresses the growth of myeloma cells.
Yurie Nagai, Naoya Mimura, Ola Rizq, Yusuke Isshiki, Motohiko Oshima, William Lennox

Sci Rep· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
DHODH inhibition synergizes with DNA-demethylating agents in the treatment of myelodysplastic syndromes.
Kensuke Kayamori, Yurie Nagai, Cheng Zhong, Satoshi Kaito, Daisuke Shinoda, William Lennox

Blood Adv· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of the novel tubulin polymerization inhibitor PTC-028 for myelodysplastic syndrome.
Cheng Zhong, Kensuke Kayamori, Shuhei Koide, Daisuke Shinoda, Motohiko Oshima, William Lennox

Cancer Sci· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting of Hematologic Malignancies with PTC299, A Novel Potent Inhibitor of Dihydroorotate Dehydrogenase with Favorable Pharmaceutical Properties.
Liangxian Cao, Marla Weetall, Christopher Trotta, Katherine Cintron, Jiyuan Ma, William Lennox

Mol Cancer Ther· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of Novel Small Molecule Inhibitors of VEGF Expression in Tumor Cells Using a Cell-Based High Throughput Screening Platform.
Liangxian Cao, Marla Weetall, Jenelle Bombard, Hongyan Qi, Tamil Arasu, William Lennox

PLoS One· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
6
6-(Azaindol-2-yl)pyridine-3-sulfonamides as potent and selective inhibitors targeting hepatitis C virus NS4B.
Guangming Chen, Hongyu Ren, Nanjing Zhang, William Lennox, Anthony Turpoff

Bioorg Med Chem Lett· February 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structure-activity relationship (SAR) optimization of 6-(indol-2-yl)pyridine-3-sulfonamides: identification of potent, selective, and orally bioavailable small molecules targeting hepatitis C (HCV) NS4B.
Nanjing Zhang, Xiaoyan Zhang, Jin Zhu, Anthony Turpoff, Guangming Chen, William Lennox

J Med Chem· March 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of novel HCV inhibitors: synthesis and biological activity of 6-(indol-2-yl)pyridine-3-sulfonamides targeting hepatitis C virus NS4B.
Xiaoyan Zhang, Nanjing Zhang, Guangming Chen, Anthony Turpoff, Hongyu Ren, William Lennox

Bioorg Med Chem Lett· July 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of N1-(6-chloroimidazo[2,1-b][1,3]thiazole-5-sulfonyl)tryptamine as a potent, selective, and orally active 5-HT(6) receptor agonist.
Derek C Cole, Joseph R Stock, William J Lennox, Ronald C Bernotas, John W Ellingboe

J Med Chem· November 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Conformationally constrained N1-arylsulfonyltryptamine derivatives as 5-HT6 receptor antagonists.
Derek C Cole, William J Lennox, Joseph R Stock, John W Ellingboe, Hossein Mazandarani

Bioorg Med Chem Lett· November 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
N1-arylsulfonyl-3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indole derivatives are potent and selective 5-HT6 receptor antagonists.
Derek C Cole, John W Ellingboe, William J Lennox, Hossein Mazandarani, Deborah L Smith

Bioorg Med Chem Lett· January 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of 5-arylsulfonamido-3-(pyrrolidin-2-ylmethyl)-1H-indole derivatives as potent, selective 5-HT6 receptor agonists and antagonists.
Derek C Cole, William J Lennox, Sabrina Lombardi, John W Ellingboe, Ronald C Bernotas

J Med Chem· January 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bernard of Gordon on Epilepsy.
William G Lennox

Ann Med Hist· September 1941

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antonius Guainerius on Epilepsy.
William G Lennox

Ann Med Hist· November 1940

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
J
John of Gaddesden on Epilepsy.
William G Lennox

Ann Med Hist· May 1939

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis